Overcoming Limitations of T-Cell Engagers with Bispecifics Providing Costimulatory Signals
- The use of molecules capable of activating the immune system by targeting costimulatory signals on T cells has not been fully explored yet
- NI-4101 is a FcRH5xCD28 bispecific antibody which has the potential to expand the number of patients who benefit from TCE-based therapies, possibly leading to deeper and more durable responses
- NI-3201, a PD-L1xCD28 bispecific antibody, additionally blocks the PD-L1/PD-1 immune checkpoint pathway, thus overcoming two major immune suppression mechanisms at once